Survival
98%
survival to date across treated cases
BIO-PLY™
A first-in-class, triple-action peptide biologic.
Developed specifically for equine septic joints, BIO-PLY™ addresses all three major challenges — infection, inflammation, and tissue damage — in a single ready-to-use treatment.
AntimicrobialAnti-inflammatoryChondroprotective
The problem
Septic arthritis is devastating to horses.
When a joint, tendon sheath, or bursa becomes infected, the current standard of care often can't keep up, and the damage compounds fast.
Current standard of care
Infection that won't clear
Bacteria hide in antibiotic-resistant biofilms, so standard antibiotics can't reach or clear the infection.
Cartilage destroyed
Runaway inflammation eats away at cartilage and soft tissue, often irreversibly.
Careers and lives lost
Many affected horses never return to performance, and some do not survive.
With BIO-PLY™
BIO-PLY™ succeeds where standard of care fails.
Goes after the infection
Directly antibacterial, active even against the biofilms that shield bacteria from antibiotics.
Calms joint inflammation
Resolves runaway inflammation without shutting down a productive immune response.
Protects cartilage
Helps preserve cartilage and soft tissue from the irreversible damage of joint sepsis.
The solution
What is BIO-PLY™?
A platelet-derived peptide biologic manufactured for consistency, quality, and clinical performance.
BIO-PLY™ is a platelet-derived peptide biologic developed for the treatment of equine septic synovial infections. Laboratory and veterinary studies have demonstrated antibacterial, immune-modulating, and tissue-protective activity, supporting its ability to help control infection while preserving joint health.
BIO-PLY™ is manufactured through a carefully controlled process focused on consistency, safety, and quality. Platelets are sourced from a closed, screened donor herd, and every production lot undergoes comprehensive quality and potency testing before release. BIO-PLY™ is currently advancing through FDA-authorized clinical development for equine septic synovial infections under the oversight of the FDA-CVM.
- Platelet-derived
- Peptide biologic
- cGMP manufactured
- Health-screened donor herd
- Lot release tested
FDA-supervised pilot trial
Delivering great results for equine health.
Early findings from our multi-site clinical study are encouraging: BIO-PLY™ is showing improved outcomes versus the current standard of care for septic synovitis, without a single adverse event reported to date.
Return to athletic function
85%
returned to athletic function
FDA-supervised, multi-site clinical study · data collection is ongoing, so results are subject to change. Standard-of-care figures are historical, drawn from a meta-analysis of published literature.
Patient story
From career-ending injury to the winner's circle.
Far Better, a 7-year-old pacing gelding given a prognosis of "won't race again."
Before BIO-PLY™
Standard of care fails
- Severe septic joint
- Multiple surgeries
- Not responding to antibiotics
- Two years out of racing
- Prognosis: "won't race again"
After BIO-PLY™
Back to racing
- Rapid reduction in swelling
- Restored joint flexibility
- Returned to racing in month 4
- Back in the winner's circle in month 5
Veterinarian voices
Heard from the field.
Development status
Where BIO-PLY™ is today
- Discovery
- Preclinical
- Clinical trials
- FDA pathway*
- FDA approved
Septic synovial infections · advancing through the FDA approval process
*BIO-PLY™ is participating in the FDA Center for Veterinary Medicine (FDA-CVM) Animal Cell, Tissue, and Gene Therapy (ACTP) Veterinary Innovation Program. Participation reflects active collaboration with the FDA-CVM to support product development and regulatory review, and does not constitute FDA approval.
See the full product pipelineAvailable now
Ready to put BIO-PLY™ to work?
Request access below — it's the official channel for veterinary practices to request BIO-PLY™.
Contact us